Clinical Trial Update: Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating the safety and tolerability of TOP-N53 applied to digital ulcers in systemic sclerosis, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• TOP-N53

Snippet

Sponsor: Topadur Pharma AG | Conditions: Digital Ulcers in Systemic Sclerosis | Phase 2 | Status: RECRUITING